Alluvi, formerly BI 4744, represents a promising breakthrough in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable results in clinical studies, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/